CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
LY2624803 - Solution +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01784614
NCT01784614Phase 1Completed
CompareCT.gov

Pharmacodynamics and Pharmacokinetics of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Japanese Subjects

Eli Lilly and Company·interventional·Posted Feb 6, 2013·Updated Jan 28, 2016

In Brief

A Phase 1 clinical trial evaluating LY2624803 - Solution, LY2624803 - Capsule, and 2 other interventions for Sleep Initiation and Maintenance Disorders. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy Japanese participants. The study has four treatment periods. Participants will receive a single dose of LY2624803 or placebo in each treatment period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Initiation and Maintenance Disorders
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 6, 2013
Enrollment StartSep 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.4 years ago

Interventions

LY2624803 - Solutiondrug

Administered orally as reconstituted solution

LY2624803 - Capsuledrug

Administered orally as a capsule

Placebo - Solutiondrug

Administered orally as solution

Placebo - Capsuledrug

Administered orally as a capsule